1-9 of 9
Irina Dyagil
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Baseline Characteristics of CML Patients Accross Europe - Comparing Real-World Patients with Patient Collectives Included in Clinical Trials

Michele Baccarani, MD, Verena Sophia Hoffmann, Gianantonio Rosti, Fausto Castagnetti, Susanne Saussele, MD, Joelle Guilhot, PhD, Bengt Simonsson, MD PhD, Juan Luis Steegmann, MD PhD, Jiri Mayer, Prof., MD PhD, Karel Indrak, MD PhD, Anna G. Turkina, MD PhD, Andrey Zaritskey, Boris Labar, MD PhD, Irena Zupan, MD PhD, Noortje Thielen, MD, Richard E. Clark, MD, Josef Thaler, MD, Frederiki Melanthiou, Hele Everaus, MD PhD, Kimmo Porkka, MD PhD, Andrija Bogdanovic, Gabriele Schubert-Fritschle, Dr., Panagiotis Panagiotidis, MDPhD, Tamas Masszi, MD, Sandra Lejniece, PhD MD, Laimonas Griskevicius, Andrzej Hellmann, Witold Prejzner, Tomasz Sacha, MD PhD, Antonio Almeida, MD PhD, Irina Dyagil, Adriana Colita, MD, Georgi G. Mihaylov, MD PhD, Rüdiger Hehlmann, MD, Joerg Hasford, MD, Doris Lindoerfer
Journal: Blood
Blood (2014) 124 (21): 3160.
https://doi.org/10.1182/blood.V124.21.3160.3160
Published: 2014
Journal Articles

CML Patients In Clinical Trials Represent Fairly Well The General Population Of CML Patients: A Comparative Analysis Of 5803 Patients From The EUTOS Registry

Verena S Hoffmann, PhD, Doris Lindoerfer, Dipl.-Inf., Markus Pfirrmann, PhD, Susanne Saussele, MD, Andreas Hochhaus, MD, Jutta Engel, PhD, MD, Joelle Guilhot, PhD, Gianantonio Rosti, Jiri Mayer, MD, PhD, Karel Indrak, MD, Fausto Castagnetti, Anna Turkina, Andrey Zaritskey, MD, PhD, Juan Luis Steegmann, MD, PhD, Andrzej Hellmann, Noortje Thielen, MD, Francisco Cervantes, MD, PhD, Bengt Simonsson, MD, PhD, Adriana Colita, MD, Richard E. Clark, MBBS, MD, FRCP, FRCPath, Antonio Almeida, MD, PhD, Boris Labar, MD, PhD, David Marin, MD, Gert J. Ossenkoppele, MD PhD, Andrija Bogdanovic, Irina Dyagil, Kimmo Porkka, MD, PhD, Stephen O'Brien, Laimonas Griskevicius, Panagiotis Panagiotidis, MD, Josef Thaler, MD, Irena Zupan, MD, PhD, Sandra Lejniece, PhD, MD, Hele Everaus, MD, PhD, Tamás Masszi, MD, PhD, Frederiki Melanthiou, Rüdiger Hehlmann, Joerg Hasford, MD, Michele Baccarani, MD
Journal: Blood
Blood (2013) 122 (21): 2735.
https://doi.org/10.1182/blood.V122.21.2735.2735
Published: 2013
Journal Articles

Efficacy and Tolerability of Bosutinib and Imatinib in Older Versus Younger Patients with Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia–BELA Trial

Carlo Gambacorti-Passerini, Tim H Brümmendorf, Dong-Wook Kim, Irina Dyagil, Hagop M Kantarjian, Dmitri Pavlov, Karin Gogat, Ladan Duvillie, Mark Shapiro, Jorge E Cortes, MD
Journal: Blood
Blood (2012) 120 (21): 4442.
https://doi.org/10.1182/blood.V120.21.4442.4442
Published: 2012
Journal Articles

Preliminary Results of a Phase II Open-Label, Randomized Study of the BH3 Mimetic Protein Navitoclax (ABT-263) with or without Rituximab for Treatment of Previously Untreated B-Cell Chronic Lymphocytic Leukemia

Herbert Eradat, MD, MS, Sebastian Grosicki, MD, PhD, John Catalono, MD, Walter Cosolo, MD, Irina Dyagil, Thomas J Kipps, MD, PhD, Beiyao Zheng, Sreeni Yalamanchili, Srikumar Sahasranaman, Deborah Hurst, MD, William Ho, MD, PhD, Halyna Pylypenko, MD
Journal: Blood
Blood (2012) 120 (21): 190.
https://doi.org/10.1182/blood.V120.21.190.190
Published: 2012
Journal Articles

Busulfan Exposure Decrease CCyR Rate On Imatinib Therapy - Impact On Recent Pretreatment

Irina Dyagil, Elza Lomaia, Kudrat Abdulkadirov, Elena Goryunova, Natalia Lazorko, Ekaterina Romanova, Eugenia Sbityakova, Alla Abdulkadirova, Irina Martinkevich, Vera Udalieva, Elena Usacheva, Irina Zotova, Vasiliy Shuvaev, Elena Machulaitene, Ekaterina Poznyak, Maria Ivanova, Natalia Ilina, Elena Koryagina, Tatiana Shneider, Svetlana Stepanova, Irina Dmitrenko, Natalia Babkina, Tatiana Perekhrestenko, Zvenyslava Masliak, Andrey Zaritskey
Journal: Blood
Blood (2011) 118 (21): 4452.
https://doi.org/10.1182/blood.V118.21.4452.4452
Published: 2011
Journal Articles

An Ongoing Phase 3 Study of Bosutinib (SKI-606) Versus Imatinib In Patients with Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia

Carlo Gambacorti-Passerini, Dong-Wook Kim, Hagop M. Kantarjian, Tim H. Brummendorf, Irina Dyagil, Laimonas Griskevicius, Hemant Malhotra, Yeow-Tee Goh, Junyuan Wang, Karin Gogat, Jorge Cortes
Journal: Blood
Blood (2010) 116 (21): 208.
https://doi.org/10.1182/blood.V116.21.208.208
Published: 2010
Journal Articles

High Dose Imatinib Induction Therapy (800 mg/day, 6 Months) In Pre-Treated Chronic Phase CML Patients Improves Cytogenetic and Molecular Responses but Does Not Improve Overall and Progression Free Survival – Final Results of the CELSG Phase III CML11 “ISTAHIT” Trial

Andreas L Petzer, Dominic Fong, Thomas Lion, Irina Dyagil, Zvenyslava Masliak, Andrija Bogdanovic, Laimonas Griskevicius, Sandra Lejniece, Stefan Goranov, Liana Gercheva, Aleksandar Stojanovic, Dontcho Peytchev, Nikolay Tzetkov, Rasa Griniute, Radka Oucheva, Thomas Grubinger, Marthin Kwakkelstein, Francesca Rancati, Günther A Gastl, Dominik Wolf
Journal: Blood
Blood (2010) 116 (21): 2271.
https://doi.org/10.1182/blood.V116.21.2271.2271
Published: 2010
Journal Articles

CELSG CML 11 “ISTAHIT” Phase III Study – Planned Interim Analysis: High Doses of Imatinib Mesylate (800mg/day) Significantly Improve Rates of Major and Complete Cytogenetic Remissions (MCR, CCR) in Pretreated Ph + /BCR-ABL + CML Patients in Chronic Phase.

Andreas L. Petzer, MD, Dominik Wolf, MD, Dominic Fong, MD, Thomas Lion, MD, Irina Dyagil, MD, Zvenyslava Masliak, MD, Darinka Boskovic, MD, Laimonas Griskevicius, MD, Sandra Lejniece, MD, Stefan Goranov, MD, Liana Gercheva, MD, Aleksandar Stojanovic, MD, Dontcho Peytchev, MD, Nikolay Tzvetkov, MD, Rasa Griniute, MD, Radka Oucheva, MD, Hanno Ulmer, PhD, Marthin Kwakkelstein, MD, Gianluca Fincato, MD, Guenther Gastl, MD
Journal: Blood
Blood (2008) 112 (11): 1112.
https://doi.org/10.1182/blood.V112.11.1112.1112
Published: 2008
Journal Articles

Multicenter, Randomized, Phase III Study Comparing Imatinib (Glivec) Standard Dose (400 mg/d) with Imatinib High Dose Induction (800 mg/d) Followed by Imatinib Maintenance (400 mg/d) in Patients with Pretreated Ph + /BCR-ABL + CML in Chronic Phase - Results from the First Planned Interim Analysis (CELSG-CML 11 ISTAHIT Study).

Andreas L. Petzer, MD, Dominik Wolf, MD, Dominik Fong, MD, Thomas Lion, MD, PhD, Irina Dyagil, MD, Zvenyslava Masliak, MD, Darinka Boskovic, MD, Laimonas Griskevicius, MD, Sandra Lejniece, MD, Emil Spasov, MD, Liana Gercheva, MD, Aleksandar Stojanovic, MD, Dontcho Peytchev, MD, Nikolay Tzvetkov, MD, Rasa Griniute, MD, Atanas Stanchev, MD, Martin Kwakkelstein, MD, Hanno Ulmer, PhD, Guenther A. Gastl, MD
Journal: Blood
Blood (2007) 110 (11): 1048.
https://doi.org/10.1182/blood.V110.11.1048.1048
Published: 2007